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Introduction: Previous research showed that the addition of bevacizumab (a monoclonal 
antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted in a 
significant efficacy benefit in the treatment of selected patients with advanced nonsquamous 
non–small cell lung cancer (NSCLC). However, the occurrence and management of adverse 
events (AEs) during long-term maintenance treatment with bevacizumab is not well known.
Methods: This report presents a descriptive analysis, including the management of AEs, of 
four patients with advanced NSCLC, who received a relatively long period of bevacizumab 
maintenance treatment.
Results: In patient 1, a 72-year-old retired man with stage cT2N2M1b NSCLC, the only AE 
related to bevacizumab was a grade 1 rhinorrhea. Treatment resulted in a stable disease, with 
duration of response of 38 months. Patient 2 had NSCLC stage cT4N3M1b and developed a 
cavitation and infection after the first cycle of chemotherapy and bevacizumab, which caused a 
temporary decrease of her quality of life. Bevacizumab therapy resulted in a partial response, 
with duration of response of 15 months. A 52-year-old female (patient 3) with stage T2bN2M1a 
NSCLC is currently under treatment and has so far received 42 cycles of maintenance bevaci-
zumab, with stabilized response (duration of response of 29 months) and no noteworthy AEs. 
The last patient is a 74-year-old male farmer with NSCLC T1N0M1, whose response has lasted 
for more than 3 years, with until now, no AEs.
Conclusion: Our retrospective findings of these four patients show the long-term efficacy and 
safety of bevacizumab treatment in a real-life setting.
Keywords: lung cancer, non–small cell lung cancer, maintenance treatment, safety 
management
Introduction
Lung cancer is the leading cause of cancer-related mortality in the United States 
and Western Europe. Around 85% of the patients with lung cancer have non–small 
cell lung cancer (NSCLC), of which the majority are in advanced stage (stage IV).1 
According to current European guidelines,2 the first-line treatment for patients with 
stage IV NSCLC should take into account the histology, molecular pathology, age, 
performance status (PS), comorbidities, and the patient’s preferences. In patients 
with a performance status of 0–1, platinum-based combination chemotherapy should 
be offered. For patients with nonsquamous histology, pemetrexed is preferred to 
gemcitabine. Bevacizumab, a monoclonal antibody against vascular endothelial 
growth factor (VEGF), can be added to platinum-based chemotherapy in eligible 
patients. Previous trials and meta-analyses showed that the addition of bevacizumab 
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to chemotherapy in the treatment of selected patients with 
advanced  nonsquamous NSCLC resulted in a significant 
efficacy benefit.3–8 The initial bevacizumab study in NSCLC 
patients showed a median progression-free survival (PFS) 
benefit of 1.7 months and a median overall survival (OS) 
advantage of 2 months.3 In specifically the adenocarci-
noma patients, the median OS benefit has been shown to 
be 3.9 months.4
In an open-label, phase IV trial, the safety and efficacy 
of first-line bevacizumab combined with standard che-
motherapy regimens was confirmed in clinical practice.9 
The results confirmed the manageable safety profile of 
first-line bevacizumab in combination with various stan-
dard chemotherapy regimens for treatment of advanced 
nonsquamous NSCLC.9 Adverse events (AEs) of grade 3 
and higher that seem to be specifically related to bevaci-
zumab treatment are: hypertension, occurring in ∼7% of 
patients; bleeding, in ∼4% of patients; and proteinuria, in 
∼3% of patients.3,9
After the induction treatment of 4–6 cycles of chemo-
therapy in combination with bevacizumab, treatment with 
bevacizumab monotherapy is continued until progression 
of the disease or intolerability due to toxicity. The reported 
median number of cycles for patients treated with bevaci-
zumab is seven, with a range varying from one to 43 cycles 
(Table 1).3,5,9
The occurrence and management of long-term AEs dur-
ing the maintenance treatment with bevacizumab is not well 
known. This report presents a descriptive analysis, includ-
ing the management of AEs, of four patients with advanced 
NSCLC who received bevacizumab both in combination with 
chemotherapy and as monotherapy during the maintenance 
phase, for a relatively long follow-up period.
Methods
Each author had to identify the last patient from their clinical 
practice that received more than 20 cycles of bevacizumab 
treatment. Obviously, this is a highly selected cohort of 
patients, since the number of patients reaching .20 cycles 
is low in clinical practice. The stage, diagnosis, treatment 
type and duration, and the occurrence of AEs were described 
according to the National Cancer Institute (NCI) Common 
Terminology Criteria for AE (CTC-AE) 4.03. In addition, a 
description of the quality of life (QoL), as interpreted by the 
treating physician is presented. Of note; in the cases described 
in this paper, patient-reported QoL has not been taken into 
account, which could of course differ from the physician’s 
description of QoL. T
ab
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Results
Patient 1
A 72-year-old retired man with a smoking history of 
43-pack years presented to his primary care physician 
with pain in the right thorax. The pain had been present for 
2 months, especially during the nights, and had been treated 
with tramadol and diclofenac. He had no other respiratory 
symptoms (no coughing, no sputum, no hemoptysis, and no 
dyspnea), his body weight had been stable for thirty years. 
At that time, he was still able to walk the stairs without 
problems. A computed tomography (CT) scan of the tho-
rax and 18fludeoxyglucose positron emission tomography 
(18FDG-PET) showed stage cT2N2M1b lung carcinoma of 
the left lower lobe with a lytic lesion of the rib. Cytological 
analysis of the lesion in the main carina showed a large-cell, 
poorly differentiated, thyroid transcription factor (TTF)-
1-positive lung tumor; rib puncture confirmed metastatic 
disease without epidermal growth factor receptor (EGFR)/
KRAS mutation.
Next to radiotherapy for the bone metastasis in the rib, 
patient 1 received palliative chemotherapy (carboplatin area 
under the curve [AUC] 6 and paclitaxel 200 mg/m2) plus 
bevacizumab 7.5 mg/kg every 3 weeks, for 52 treatment 
cycles. He received paclitaxel 200 mg/m2 for three cycles, 
which was then stopped because of allergic reaction during 
the fourth cycle; carboplatin 6 AUC in combination with 
gemcitabine 1200 mg/m2 on days 1 and 8 was used in the 
fourth (and final) cycle of chemotherapy. Bevacizumab was 
continued as a single agent until disease progression.
AEs that occurred in this patient included grade 2 fatigue, 
grade 3 leucopenia, and grade 1 neuropathy, all of which 
developed during the chemotherapy and bevacizumab com-
bination therapy. The only AE that developed during beva-
cizumab maintenance was a grade 1 rhinorrhea. In addition, 
the patient suffered from pain in his arm, of which the exact 
cause is unknown. Due to the pain in his arm, he had difficulty 
getting in and out of his car, which he had to do more than 
100 times per day because of his work (newspaper-man). 
The maintenance treatment resulted in stable disease, with 
a duration of response of 38 months.
Patient 2
A 64-year-old housewife was referred by her primary care 
physician because of cough and pain during coughing. 
She was a smoker and had a smoking history of five packs 
per week for 40 years. The patient was in good  condition 
(Eastern Cooperative Oncology Group performance  status 
[ECOG PS] 1). Further examination revealed a lung 
 adenocarcinoma in the right upper lobe, stage cT4N3M1b 
with metastases in the left supraclavicular nodes.
Patient 2 received chemotherapy carboplatin (AUC 6) 
and paclitaxel 200 mg/m2 for four cycles in combination with 
bevacizumab 15 mg/kg every 3 weeks for 21 cycles. After 
the first cycle, hospitalization was needed due to a cavitation 
in the primary tumor and a subsequent  colonization of the 
cavity with bacteria, for which antibiotics were given. Due to 
this AE, the next cycle of chemotherapy plus bevacizumab 
was delayed for 1 week, and the dose of each of the drugs was 
adjusted to 75% of the original dosage for the additional three 
cycles. Afterwards, bevacizumab 15 mg/kg was continued 
for 21 cycles until progression.
The cavitation and infection after the first cycle caused a 
temporary decrease in her QoL. She received a blood transfu-
sion with two units of packed cells for anemia related to the 
chemotherapy bevacizumab treatment. Other AEs included 
grade 2 sensory neuropathy, probably due to paclitaxel, 
and hypertension and grade 1 proteinuria that was probably 
due to bevacizumab, all developing during the combination 
treatment. During the maintenance treatment, no additional 
toxicities were established. Due to a decrease in cough, her 
QoL improved. Treatment resulted in a partial response, with 
a duration of response of 15 months.
Patient 3
A 52-year-old female counter assistant, who had smoked 
two packs per day for 30 years, was referred to the chest 
physician because of severe chronic obstructive pulmo-
nary disease (COPD) (stage GOLD III), with extensive 
centrilobular emphysema; no previous exacerbation; no 
inhalation medication, and a focal lesion in the right upper 
lobe and multiple, small nodular lesions in both lungs. 
Upon further examination, the diagnosis was a T2bN2M1a 
NSCLC of the right upper lobe (stage IV) with an ECOG 
PS of 0. Analyses of EGFR and KRAS status were not 
possible.
Patient 3 was treated with carboplatin AUC 6, paclitaxel 
200 mg/m2, and bevacizumab 7.5 mg/kg every 3 weeks (four 
cycles), resulting in a near complete response. She stopped 
working after the diagnosis but could cope with the disease 
and therapy. During the first treatment time, she was seen 
by a mental coach.
Maintenance treatment with bevacizumab 7.5 kg/kg has 
been ongoing every 3 weeks for 42 cycles, with good 
tolerability and no noteworthy AEs, and with a stabilized 
response. Due to liver enzymes abnormalities that were 
caused by bile stones, the treatment was postponed two times. 
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No  treatment-related AEs were reported, and no concomitant 
or supportive therapy was needed.
Her QoL is currently good, the patient is in good condi-
tion, and is able to carry out daily work, but didn’t return 
to her job. During the maintenance treatment, there were no 
side effects and no complaints about the repeating hospital 
visits every 3 weeks. The maintenance treatment resulted in 
a partial response, and the patient is still on treatment, with 
a duration of response to date, of 29 months.
Patient 4
A 74-year-old male farmer (smoking history: one pack per 
day for 30 years, no longer smoking) presented with abdomi-
nal pain, fatigue, and loss of appetite. He was referred by his 
general practitioner. His chest X-ray and CT-scan showed a 
tumor in the right upper lobe, with lymphadenopathy. An 
ultrasound of his liver showed abnormalities that were com-
patible with metastasis. A bronchoscopy and liver biopsy 
confirmed the diagnosis of NSCLC stage T1N0M1. EGFR/
KRAS mutational analysis was not performed. His ECOG 
PS was 1.
The treatment plan constituted of carboplatin AUC 5, 
gemcitabine 1250 mg/m2, and bevacizumab 7.5 mg/kg every 
3 weeks in four treatment cycles, with bevacizumab every 
3 weeks as maintenance until progression. There were no side 
effects recorded. His ECOG PS improved to 0. The QoL is 
equally good. He has adjusted his activities in such manner 
that it will not interfere with his therapy schedule. A partial 
response was achieved without experiencing any AEs and 
with to date, a duration of response of 36 months.
Discussion
Various clinical trials have proved the efficacy of adding 
bevacizumab to platinum-based chemotherapy in the treat-
ment of patients with nonsquamous NSCLC, as summarized 
in Table 1. The median overall survival times for patients 
with NSCLC treated with platinum-based chemotherapy vary 
from 8–10 months, as reported in previous clinical trials.10,11 
The median number of cycles reported in clinical trials for 
patients treated with bevacizumab is seven, with a range 
of one to 43 cycles.9 Also, in clinical practice, it has been 
observed that some NSCLC patients treated with a combi-
nation of platinum-based chemotherapy and bevacizumab 
are treated for a considerably longer period of time (up to 
39 months). Four such cases were described in this report.
The AEs occurring in patients treated for four to six 
cycles with platinum-based chemotherapy and bevacizumab 
are generally well known and include bleeding, particularly 
of the nose; proteinuria; and hypertension.9 An  investigation 
was specifically conducted to indicate the risk factors for 
bleeding events, since lung bleeding, in particular, can be 
fatal;12 this investigation showed that the only risk factor 
that was associated with an increased risk of bleeding was 
cavitation at baseline.
Treatment of patients with NSCLC in the maintenance 
phase is rather new, and there is not much known about the 
long-term effects of maintenance treatment on the occur-
rence of AEs. A recent report described a retrospective 
analysis of NSCLC patients during the maintenance phase 
of study E4599 and observed grade 3 or 4 hematological 
toxicities in less than 1%; no grade 3 or 4 nausea, vomiting, 
or diarrhea; and no grade 5 toxicities.13 Most experience of 
bevacizumab maintenance treatment and toxicities has been 
with bevacizumab-treated patients with colorectal cancer.14–16 
A recent report describes the treatment of bevacizumab in 
combination with various chemotherapy schemes for 1550 
patients with metastatic colorectal cancer. In this report, it 
was also shown that bevacizumab was tolerable during the 
maintenance phase. This study reported a median treatment 
duration of bevacizumab of 6.7 months, with a range of up 
to 43 months.14 In colorectal cancer, it has also been shown, 
through patient-reported outcomes questionnaires, that 
bevacizumab does not have a negative impact on quality 
of life.16
In clinical practice, questions arise as to what AEs to 
expect during the maintenance phase of bevacizumab treat-
ment and how to practically manage them. The four cases 
described in this report suggest that the occurrence of AEs 
in the maintenance phase can be mild or even almost absent, 
which is also in line with a retrospective analysis of study 
E4599.13 Obvious examples are patients 1 and 4 described in 
this report who received bevacizumab maintenance therapy 
for over 3 years in the absence of AEs. Also particularly 
interesting, is the description of patient 2, in whom cavitation 
occurred upon treatment with bevacizumab. As described 
above, only cavitation at baseline is a risk factor for  bleeding. 
Cavitation upon treatment with bevacizumab has been 
described previously.17 In a multidisciplinary discussion 
amongst clinicians from various hospitals, it was decided 
to continue treatment of this patient; despite the cavitation 
formation, this patient underwent 21 cycles and continued 
with her daily activities, and bleeding didn’t occur.
Obviously this paper has a selection bias, as only patients 
who received long-term treatment were included. Patients 
who experienced adverse events causing treatment discon-
tinuation were not included. The aim of the present patient 
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presentation was to describe that long-term treatment can 
be possible.
Optimally, we should be able to use a biomarker to select 
“up front” the patients that will benefit from bevacizumab 
treatment for a long-term period. Continuing efforts are ongo-
ing to define a biomarker, which is described recently.18
Our present retrospective findings showed the long-term 
efficacy and safety of bevacizumab treatment, in a selected 
cohort of patients that responded well to bevacizumab treat-
ment, in a real-life setting.
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